Interestingly, BemA appeared to counteract Lira-induced upregulation of TGF-β effectors, including Smad3, a transcription factor critical for upregulating fibrotic pathways in NASH (Figure S2F). Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.